Relmada Therapeutics (RLMD) Non Operating Income (2014 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Non Operating Income data on file, last reported at $409798.0 in Q1 2026.

• On a quarterly basis, Non Operating Income fell 37.81% year-over-year to $409798.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 57.02% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 56.16% from the prior year.
• Non Operating Income for Q1 2026 stood at $409798.0, down from $465352.0 in the prior quarter.
• Over the last five years, Non Operating Income for RLMD reached as high as $5.6 million in Q2 2022 and fell as low as -$1.4 million in Q1 2022.
• Historically, Non Operating Income has averaged $891312.7 across 5 years, with a median of $690580.0 in 2023.
• On a YoY basis, Non Operating Income climbed as much as 6292.38% in 2022 and fell as far as 1536.53% in 2022.
• Year by year, Non Operating Income stood at $758055.0 in 2022, then soared by 119.53% to $1.7 million in 2023, then slumped by 74.86% to $418418.0 in 2024, then rose by 11.22% to $465352.0 in 2025, then dropped by 11.94% to $409798.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $409798.0 in Q1 2026, $465352.0 in Q4 2025, and $235850.0 in Q3 2025.